{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:32:36Z","timestamp":1778823156055,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","award":["Cancer Center Support Grant CA16672"],"award-info":[{"award-number":["Cancer Center Support Grant CA16672"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1245\/s10434-024-16382-7","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:03:58Z","timestamp":1729677838000},"page":"922-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"32","author":[{"given":"Alycia","family":"So","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine M.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Caudle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"DeSnyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T.","family":"Nead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mediget","family":"Teshome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"Suppl 1","key":"16382_CR1","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.breast.2021.11.018","volume":"62","author":"EH Hersh","year":"2022","unstructured":"Hersh EH, King TA. De-escalating axillary surgery in early-stage breast cancer. Breast. 2022;62(Suppl 1):S43\u20139. https:\/\/doi.org\/10.1016\/j.breast.2021.11.018.","journal-title":"Breast."},{"key":"16382_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College Of Surgeons Oncology Group z0011 randomized trial. Ann Surg. 2010;252:426\u201332. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f08f32.","journal-title":"Ann Surg."},{"key":"16382_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol."},{"key":"16382_CR4","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol."},{"key":"16382_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.acra.2009.01.026","volume":"16","author":"AM Kelly","year":"2009","unstructured":"Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer: Sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16:551\u201363. https:\/\/doi.org\/10.1016\/j.acra.2009.01.026.","journal-title":"Acad Radiol."},{"key":"16382_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/bjs.5209","volume":"93","author":"Y Xing","year":"2006","unstructured":"Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539\u201346. https:\/\/doi.org\/10.1002\/bjs.5209.","journal-title":"Br J Surg."},{"key":"16382_CR7","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","volume":"45","author":"CHM van Deurzen","year":"2009","unstructured":"van Deurzen CHM, Vriens BEPJ, Tjan-Heijnen VCG, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2009.08.001.","journal-title":"Eur J Cancer."},{"key":"16382_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162605","author":"C Geng","year":"2016","unstructured":"Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0162605.","journal-title":"PLoS One."},{"key":"16382_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jso.21911","volume":"104","author":"VKM Tan","year":"2011","unstructured":"Tan VKM, Goh BKP, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. J Surg Oncol. 2011;104:97\u2013103. https:\/\/doi.org\/10.1002\/jso.21911.","journal-title":"J Surg Oncol."},{"key":"16382_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173:343\u201352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7.","journal-title":"Breast Cancer Res Treat."},{"key":"16382_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41523-022-00383-4","volume":"8","author":"SP Shubeck","year":"2022","unstructured":"Shubeck SP, Morrow M, Dossett LA. De-escalation in breast cancer surgery. NPJ Breast Cancer. 2022;8:25. https:\/\/doi.org\/10.1038\/s41523-022-00383-4.","journal-title":"NPJ Breast Cancer."},{"key":"16382_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","volume":"212","author":"Chehade H El Hage","year":"2016","unstructured":"El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3398 patients. Am J Surg. 2016;212:969\u201381. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.07.018.","journal-title":"Am J Surg."},{"key":"16382_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary Nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3:549\u201355. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol."},{"key":"16382_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/tbj.12568","volume":"22","author":"G Vugts","year":"2016","unstructured":"Vugts G, Maaskant-Braat AJG, Nieuwenhuijzen GAP, Roumen RMH, Luiten EJT, Voogd AC. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer: a population-based study. Breast J. 2016;22:316\u201321. https:\/\/doi.org\/10.1111\/tbj.12568.","journal-title":"Breast J."},{"key":"16382_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/tbj.12793","volume":"23","author":"O Kantor","year":"2017","unstructured":"Kantor O, Pesce C, Liederbach E, Wang CH, Winchester DJ, Yao K. Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy? Breast J. 2017;23:554\u201362. https:\/\/doi.org\/10.1111\/tbj.12793.","journal-title":"Breast J."},{"key":"16382_CR16","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","volume":"30","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Yu H, Dugan CL, et al. Changes in surgical management of the axilla over 11 years: report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30:6401\u201310. https:\/\/doi.org\/10.1245\/s10434-023-13759-y.","journal-title":"Ann Surg Oncol."},{"key":"16382_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00000658-199907000-00011","volume":"230","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72\u20138. https:\/\/doi.org\/10.1097\/00000658-199907000-00011.","journal-title":"Ann Surg."},{"key":"16382_CR18","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1245\/s10434-022-12064-4","volume":"29","author":"SB Sanders","year":"2022","unstructured":"Sanders SB, Hoskin TL, Stafford AP, Boughey JC. Factors influencing non-sentinel lymph node involvement in patients with positive sentinel lymph node(s) after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29:7769\u201378. https:\/\/doi.org\/10.1245\/s10434-022-12064-4.","journal-title":"Ann Surg Oncol."},{"key":"16382_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s10434-999-0762-4","volume":"6","author":"JT Lenert","year":"1999","unstructured":"Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999;6:762\u20137. https:\/\/doi.org\/10.1007\/s10434-999-0762-4.","journal-title":"Ann Surg Oncol."},{"key":"16382_CR20","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304\u201311. https:\/\/doi.org\/10.1200\/JCO.2005.02.5023.","journal-title":"J Clin Oncol."},{"key":"16382_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152:665\u201370. https:\/\/doi.org\/10.1001\/jamasurg.2017.0562.","journal-title":"JAMA Surg."},{"key":"16382_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1245\/aso.2003.03.015","volume":"10","author":"KJ Van Zee","year":"2003","unstructured":"Van Zee KJ, Manasseh DME, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140\u201351. https:\/\/doi.org\/10.1245\/aso.2003.03.015.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"16382_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/SLA.0000000000002373","volume":"226","author":"JC Boughey","year":"2017","unstructured":"Boughey JC, Ballman KV, McCall LM, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg. 2017;266(4):667\u201376. https:\/\/doi.org\/10.1097\/SLA.0000000000002373","journal-title":"Ann Surg."},{"issue":"17","key":"16382_CR24","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2013ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342\u201349. https:\/\/doi.org\/10.1200\/JCO.2010.31.6950","journal-title":"J Clin Oncol."},{"issue":"4","key":"16382_CR25","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-022-12972-5","volume":"30","author":"KK Hunt","year":"2023","unstructured":"Hunt KK, Suman VJ, Wingate HF, et al. Local-regional recurrence after neoadjuvant endocrine therapy: data from ACOSOG Z1031 (Alliance) a randomized phase 2 neoadjuvant comparison between letrozole anastrozole and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer. Ann Surg Oncol. 2023;30(4):2111\u201318. https:\/\/doi.org\/10.1245\/s10434-022-12972-5","journal-title":"Ann Surg Oncol."},{"issue":"25","key":"16382_CR26","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. NEJM. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873","journal-title":"NEJM."},{"key":"16382_CR27","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25:1488\u201394. https:\/\/doi.org\/10.1245\/s10434-018-6429-2.","journal-title":"Ann Surg Oncol."},{"key":"16382_CR28","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cncr.23481","volume":"112","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Newman LA, Ayers GD, et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008;112:2646\u201354. https:\/\/doi.org\/10.1002\/cncr.23481.","journal-title":"Cancer."},{"key":"16382_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42:361\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.11.019.","journal-title":"Eur J Surg Oncol."},{"key":"16382_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-021-06249-w","volume":"187","author":"JW Chun","year":"2021","unstructured":"Chun JW, Kim J, Chung IIY, et al. Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2021;187:647\u201355. https:\/\/doi.org\/10.1007\/s10549-021-06249-w.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16382-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T19:22:34Z","timestamp":1764444154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16382-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["16382"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16382-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author disclosures have been revised.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kelly K. Hunt serves on the Medical Advisory Board of ArmadaHealth, lecture at an event sponsored by AstraZeneca, and received research funding to MD Anderson Cancer Center\u2013Cairn Surgical, Eli Lilly & Co., and Lumicell. Kevin T. Nead is a CPRIT Scholar in Cancer Research and supported by CPRIT grant RR190077. Mariana Chavez-MacGregor is a consultant for Exact Sciences, Novartis, Astra Zeneca, Merck, and Daiichi-Sankyo; received research support from the Susan G. Komen foundation (SAC220221) and the Breast Cancer Research Foundation (BCRF-23-190).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}